July 18, 2011
/PRNewswire/ -- Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and
, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT. One client will be moving into a final stage development program in oncology, leveraging PCT's expertise.
Robert A. Preti
, PhD, President of PCT said, "We are thrilled to provide support and leverage our expertise and dedicated service, comparable to what PCT has provided to Dendreon, Inc. in the recent past. For Dendreon, PCT facilitated the manufacturing and distribution of Provenge, a cell based therapy product for the treatment of prostate cancer that received FDA approval in 2010."
The newly signed agreement offers the potential for PCT to provide commercial manufacturing capacity into a multi-million dollar market should trials show that the target therapeutic fulfills its promise for patients suffering from certain types of cancer and related disorders.
In addition, PCT has received news that a second key client has extended its cGMP (current Good Manufacturing Practices) manufacturing agreement to provide for additional services for this client's development program to address disorders of the immune system. "Progenitor Cell Therapy and its management continue to receive validation that expertise in manufacturing is one of the critical elements in the development of cell therapies for the fields of regenerative medicine, immunology and oncology," said Dr.
, CEO of NeoStem. Dr. Preti added, "We are pleased to be given the opportunity to continue our successful relationships with these clients and are grateful for the trust and confidence our clients have shown in PCT's services as we look to be true partners with our contract manufacturing clients who come to us for our expertise."
About Progenitor Cell Therapy
Progenitor Cell Therapy ("PCT") serves the developing cell therapy industry that includes biotechnology, pharmaceutical and medical products companies, health care providers, and academic investigators from licensed, state-of-the-art cell therapy manufacturing facilities in
Allendale, New Jersey
Mountain View, California
. PCT supports the research of leading academic investigators designed to expedite the broad clinical application of cell therapy. PCT's core strategy is to provide a global network of cell therapy manufacturing and storage facilities and an integrated and regulatory compliant distribution capacity for the evolving cell therapy industry to meet international commercial demands.
For more information, please visit:
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem") is engaged in the development and manufacturing of cell-based therapies. Its January, 2011 acquisition of Progenitor Cell Therapy ("PCT"), and its
July 14, 2011
announcement of the signing of a merger agreement to acquire Amorcyte, Inc. ("Amorcyte"), position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy.
PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.